Sunday 18 October 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
6.04
0.64
−9.58%
Follow AGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
1.16 | 2.01 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.95 | 1.02 | 0.82 | 1.15 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.05) | (3.52) | (5.62) | (8.33) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.22 | 1.17 | 1.39 | 1.44 | |
EV/EBITDA |
3.94 | 9.34 | 0.00 | 0.00 | |
EV/Operating CF |
(1.64) | (1.66) | (2.05) | (1.72) | |
EV/FCF |
(1.64) | (1.67) | (2.06) | (1.73) | |
Quick Ratio |
0.32 | 0.36 | 0.03 | 0.03 | |
Current Ratio |
0.34 | 0.38 | 0.41 | 0.47 | |
Net Debt/EBITDA |
0.96 | (0.31) | 2.78 | (20.31) | |
Debt/Assets |
17.41% | 16.19% | 19.69% | 14.63% | |
Debt/Equity |
(0.15) | (0.13) | (0.16) | (0.12) | |
Asset Turnover |
0.74 | 0.64 | 0.50 | 0.45 | |
Operating CF/Net income |
51.65 | (0.92) | 1.56 | (0.23) | |
Capex/Depreciation |
0.46 | 0.05 | 0.00 | 0.03 | |
Interest Coverage |
0.74 | 1.03 | 0.90 | (0.35) | |
Research and Development Expense of Revenue |
42.76% | 35.04% | 21.96% | 78.04% | |
Selling, General and Administrative Expense of Revenue |
24.53% | 20.33% | 35.95% | 35.92% | |
Intangible Assets out of Total Assets |
0.16 | 0.15 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
10.45% | 3.25% | 10.12% | 10.72% | |
Graham Net Nets |
(2.37) | (2.52) | (3.98) | (3.10) | |
Graham Number |
0.00 | 0.00 | 9.17 | 20.25 | |
Earnings Yield |
86.48% | 49.70% | (12.74%) | (53.77%) | |
Free Cash Flow Yield |
(77.60%) | (68.76%) | (82.30%) | (72.46%) | |
Revenue per Share |
0.84 | 0.89 | 1.15 | 0.95 | |
Operating CF per Share |
(0.75) | (0.95) | (0.56) | (0.46) | |
Capex per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.75) | (0.95) | (0.56) | (0.46) | |
Cash per Share |
0.45 | 0.92 | 0.10 | 0.11 | |
Shareholders Equity per Share |
(4.98) | (6.01) | (9.34) | (8.81) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.98) | (6.01) | (9.34) | (8.81) | |
Free Cash Flow |
(30.96) | (35.92) | (16.62) | (14.66) | |
Working Capital |
(153.01) | (153.95) | (190.05) | (153.18) | |
Capital Expenditures |
0.24 | 0.03 | 0.00 | 0.08 | |
Net Current Asset Value |
(299.73) | (319.15) | (371.22) | (380.81) | |
EV/EBIT |
4.46 | 17.75 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
3.49 | 15.46 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.96 | 27.21 | 3.71 | 3.24 | |
Average Payables |
66.69 | 67.66 | 72.23 | 65.59 | |
Average Assets |
178.96 | 193.33 | 226.53 | 236.19 | |
Average Common Equity |
(271.08) | (275.19) | (292.14) | (276.34) |
Columns are period end dates